Varicella-Zoster Virus (VZV) Meningitis in an Immunocompetent Adult after BNT162b2 mRNA COVID-19 Vaccination: A Case Report

Varicella-Zoster Virus (VZV) Meningitis in an Immunocompetent Adult after BNT162b2 mRNA COVID-19 Vaccination: A Case Report

We present, to our knowledge, the second case report of a 46-year old female who developed varicella-zoster virus (VZV) meningitis after BNT162b2 mRNA COVID-19 vaccination. The patient is immunocompetent and has no known predisposing risk factors for developing VZV meningitis. The patient received a...

Full description

Bibliographic Details
Main Authors:	R. Medhat, R. El Lababidi, M. Abdelsalam, A. Nusair
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 SARS-CoV-2 BNT162b2 mRNA COVID-19 vaccination Varicella-zoster virus
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971222002004

Similar Items

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024-02-01)

Varicella zoster meningitis following COVID-19 vaccination: a report of two cases
by: Marturod Buranasakda, et al.
Published: (2022-06-01)

Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
by: Ryutaro Tanizaki, et al.
Published: (2022-01-01)

Varicella Zoster Virus (VZV)-Human Neuron Interaction
by: Don Gilden, et al.
Published: (2013-09-01)

Varicella Zoster Co-Infection in a Patient with COVID-19
by: Hakan Oguzturk, et al.
Published: (2020-12-01)

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”
by: Ziying Vanessa Lim, MBBS, MRCP, MMed, et al.
Published: (2022-05-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

Zoster Meningitis in an Immunocompetent Child after COVID-19 Vaccination, California, USA
by: Sarah K. Daouk, et al.
Published: (2022-07-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
by: Efrén Murillo-Zamora, et al.
Published: (2021-07-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022-06-01)

Computed tomography manifestations of a case of varicella zoster virus (VZV) pneumonia
by: Minlong Zhang, et al.
Published: (2023-12-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Varicella zoster virus and meningitis in immunocompetent patients: Specificity and questions
by: Marion Gaudin, et al.
Published: (2022-01-01)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
by: Erez Bar-Haim, et al.
Published: (2022-05-01)

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

Varicella zoster virus (VZV)-specific immunity and subclinical VZV reactivation in patients with autoimmune diseases
by: Kwang-Hoon Lee, et al.
Published: (2021-07-01)

Varicella-Zoster Virus Encephalitis in an Immunocompetent Adult with Disseminated Cutaneous Herpes Zoster after Testosterone Booster Supplements: Case Report
by: Ghada Alhayaza, et al.
Published: (2022-06-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
by: Erdal Yavuz, et al.
Published: (2022-04-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
by: Flavia Beccia, et al.
Published: (2023-02-01)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
by: Gilbert T. Chua, et al.
Published: (2022-12-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Intratracheal inoculation of human varicella zoster virus (VZV; MAV strain) vaccine successfully induced VZV IgG antibodies in rhesus monkeys
by: Jong-Min Kim, et al.
Published: (2021-05-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
by: Louise Murdoch, et al.
Published: (2023-09-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Varicella Zoster Virus-Associated Meningitis as a Rebound Varicella Zoster Disease after Antiviral Discontinuation
by: Tetsuko Sato, et al.
Published: (2021-02-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
by: Areti Tychala, et al.
Published: (2021-12-01)

Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report
by: Colm Kerr, et al.
Published: (2022-01-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation
by: Francesca Lucca, et al.
Published: (2023-01-01)

Meningitis without Rash after Reactivation of Varicella Vaccine Strain in a 12-Year-Old Immunocompetent Boy
by: Sibylle Bierbaum, et al.
Published: (2023-01-01)

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
by: Nikolaos Syrigos, et al.
Published: (2022-05-01)

Varicella pneumonia in an immunocompetent child: A case report
by: Pramodman Singh Yadav, et al.
Published: (2023-01-01)